CoV-GLUE Lineage

CoV-GLUE Lineage: B.1.426

Table of countries and their respective (filtered) sequence count for the lineage 'B.1.426'.

Lineage	Country	Count	EarliestEpiWeek	LatestEpiWeek	View Mutations	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66
B.1.426	All	991	15	66	Mutations	6	7	22	28	22	162	123	141	68	5	93	35	3	8	33	22	24	27	52	25	30	7	1	2	1	1	1	2	3	3	5	5	3	1	6	1	0	2	2	1	2	3	0	1	1	0	0	0	0	0	0	1
B.1.426	USA	961	15	66		6	7	22	28	22	162	123	141	68	5	93	35	3	8	32	22	24	19	45	25	28	2	0	0	0	1	1	1	3	3	5	5	2	1	6	1	0	2	2	1	2	3	0	1	0	0	0	0	0	0	0	1
B.1.426	PUERTO_RICO	23	29	38		0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	6	7	0	2	5	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
B.1.426	NORTHERN_MARIANA_ISLANDS	2	32	32		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
B.1.426	HONG_KONG	2	42	47		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
B.1.426	AUSTRALIA	1	38	38		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
B.1.426	CANADA	1	39	39		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
B.1.426	TURKEY	1	59	59		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0

CoV-GLUE is still in development. CoV-GLUE was originally developed as part of COG-UK by Josh Singer using the GLUE framework at the MRC-University of Glasgow Centre for Virus Research (CVR). In 2021 it was redeveloped by Richard Orton to scale to the millions of genome sequences available. We acknowledge support from the MRC (MC_UU_12014/12), WT (220977/Z/20/Z) and UKRI G2P (MR/W005611/1). Please contact Richard Orton with any queries: Richard.Orton@glasgow.ac.uk

CoV-GLUE uses sequence data from GISAID. GISAID data provided via this web application is subject to GISAID's Terms and Conditions.